The University of Chicago Header Logo

Connection

Samuel L. Volchenboum to Male

This is a "connection" page, showing publications Samuel L. Volchenboum has written about Male.
Connection Strength

0.207
  1. Obtaining Knowledge in Pathology Reports Through a Natural Language Processing Approach With Classification, Named-Entity Recognition, and Relation-Extraction Heuristics. JCO Clin Cancer Inform. 2019 08; 3:1-8.
    View in: PubMed
    Score: 0.034
  2. Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma. Pediatr Blood Cancer. 2018 12; 65(12):e27417.
    View in: PubMed
    Score: 0.032
  3. Association Between In-Hospital Critical Illness Events and Outcomes in Patients on the Same Ward. JAMA. 2016 12 27; 316(24):2674-2675.
    View in: PubMed
    Score: 0.029
  4. A subset of image-defined risk factors predict completeness of resection in children with high-risk neuroblastoma: An international multicenter study. Pediatr Blood Cancer. 2024 Oct; 71(10):e31218.
    View in: PubMed
    Score: 0.012
  5. Extracting Electronic Health Record Neuroblastoma Treatment Data With High Fidelity Using the REDCap Clinical Data Interoperability Services Module. JCO Clin Cancer Inform. 2024 May; 8:e2400009.
    View in: PubMed
    Score: 0.012
  6. Advancing clinical and translational research in germ cell tumours (GCT): recommendations from the Malignant Germ Cell International Consortium. Br J Cancer. 2022 11; 127(9):1577-1583.
    View in: PubMed
    Score: 0.011
  7. Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO Precis Oncol. 2021; 5.
    View in: PubMed
    Score: 0.010
  8. Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma. JAMA Netw Open. 2021 07 01; 4(7):e2116248.
    View in: PubMed
    Score: 0.010
  9. Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. J Immunother Cancer. 2021 07; 9(7).
    View in: PubMed
    Score: 0.010
  10. Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 2017 Nov; 102(5):859-869.
    View in: PubMed
    Score: 0.007
  11. Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2017 02; 72:177-185.
    View in: PubMed
    Score: 0.007
  12. Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. Eur J Cancer. 2016 09; 65:1-10.
    View in: PubMed
    Score: 0.007
  13. A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatr Blood Cancer. 2016 08; 63(8):1349-56.
    View in: PubMed
    Score: 0.007
  14. Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study. J Clin Oncol. 2016 Mar 01; 34(7):740-6.
    View in: PubMed
    Score: 0.007
  15. Second malignancies in patients with neuroblastoma: the effects of risk-based therapy. Pediatr Blood Cancer. 2015 Jan; 62(1):128-33.
    View in: PubMed
    Score: 0.006
  16. Development of warm auto- and allo-antibodies in a 3-year old boy with sickle cell haemoglobinopathy following his first transfusion of a single unit of red blood cells. Blood Transfus. 2010 Apr; 8(2):126-8.
    View in: PubMed
    Score: 0.004
  17. Characterization of molecular defects in isovaleryl-CoA dehydrogenase in patients with isovaleric acidemia. Biochemistry. 1998 Jul 14; 37(28):10325-35.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.